에 대한 최신 뉴스 Critical Infr Techs (OTC:CITLF) 주식

Critical Infrastructure Technologies Ltd designs and develops rapidly deployable infrastructure and power systems to support life and mission-critical applications. The company's product set is a range of rapidly deployable, high-capacity communications platforms called the NEXUS 16 and CiNet. The NEXUS 16 is a fully integrated, high-capacity communications platform that can be quickly and safely transported to remote and hostile locations and be fully operational and transmitted in under 60 minutes. CiNet was built to support the Nexus products and provide seamless integration into the operator's own Network Management Systems.

CRITICAL INFRASTUCTRE TCH by Critical Infrastructure Technologies Ltd.

Critical Infrastructure Technologies Ltd

WIIM

Trade Desk shares are trading lower after Wells Fargo downgraded the stock from Overweight to Equal-Weight and lowered its price target from $74 to $68.

Markets have continued to grind upward despite the short-lived Israel-Iran war, the <a href="https://www.benzinga.com/personal-finance/management/25/06/46011739/jerome-powell-led-fed-has-left-interest-rate-unchanged-what-does-it-mean-for-savings-mortgages-credit-cards-and-your-bank-account">Fed&#8217;s pause</a> on interest rate cuts and what feels like seemingly bearish headlines every day.
With stocks determined to keep climbing, albeit slowly, I looked for a company that will have strength going forward, and landed on semiconductor giant Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>).
With the chip and AI rally showing no signs of slowing down, <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46121658/micron-impresses-wall-street-with-strong-q3-earnings-continued-strength-in-ai-data-center">Micron</a> seems set to benefit. At the same time, the stock has not been rising as astronomically fast as some other chip competitors, at least not yet.
That&#8217;s a very good thing for the trade I have in mind today.
<h2 class="wp-block-heading">How The Pros Are Trading Strength Into Q3 — Live Tuesday</h2>
Most traders chase headlines. The pros focus on trends that last. This Tuesday at 6 PM ET, see how Tim Melvin, Ryan Faloona, and Anne-Marie Baiynd are using market strength, momentum signals, and long-term setups to stay ahead of the next big move. Their tactics are precise and built for this market. Register <a href="https://benzinga.zoom.us/webinar/register/WN_OJ2FBspHSJSSVNlW8zGapw/?">HERE</a> while limited seats are still available.
Here&#8217;s a simple trade to help boost your returns on Micron.
The trade I have in mind is a leap covered call. A leap is an options position that expires well into the future, usually after one year or more. For us today, we&#8217;ll be using options that expire in June 2026.
A covered call, meanwhile, involves owning the underlying stock (Micron, in this case) while at the same time selling calls on that stock to collect premiums.
The selling of the call option well into the future allows the trader to hold the stock at a discount and if the stock continues to rise, the call option can be covered and a new option opened against the stock (commonly called rolling the strike) to continue to both hold the stock and collect more revenue as time moves forward and the stock continues to climb.
If the stock fades, we have a solid cushion of profit the short call provides.&nbsp;
As I&#8217;m writing this, Micron&#8217;s relative resistance zone is around $157, while support sits near $95. Because of that, here&#8217;s how I&#8217;m structuring this Micron covered call:
<ul class="wp-block-list">
<li>Buy 100 shares of MU – price at this writing is $127.25 per share</li>
<li>Sell to Open 1 MU 18 Jun 2026 130 calls – currently priced at $24.50 </li>
</ul>
The breakeven prices of the stock at expiration on this trade is calculated by subtracting the credit received against the cost of the stock = $12,725 &#8211; $2,450 =$10,275, less commissions. This implies the actual cost of each share would be reduced to $102.75, a 20% discount.&nbsp;
The possible ways to leave the trade are:
<ol class="wp-block-list">
<li>Hold the stock and the option until expiration of June, 2026. If the price of the stock is above $130, the trader will relinquish the stock at $130 collecting the difference between the actual cost of the shares ($102.75 and the $130 strike price = $130 -$102.75 = $27.25 less commissions or 26 % return). </li>
<li>Set an alert for $102.75 – the breakeven price. Sell the entire position if your risk thresholds are breached. </li>
</ol>
A trader who is bullish on Micron might say that you should sell the calls much further out of the money &#8211; that is, with a much higher strike price. That&#8217;s true, but if the market has any significant retracements, selling the strike at the money provides a tidy cushion of support while still buying the stock for potential upside.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

Trading Ideas

This Week's Best Chip Stock Trade: Micron Technology

After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) appears to be <a href="https://www.benzinga.com/general/health-care/25/05/45208077/elanco-animal-health-sells-xdemvy-royalties-to-blackstone-in-295-million-deal-to-lower-debt">turning a corner</a>. 
What Happened: Investor meetings hosted by William Blair this week gave analysts enough confidence to upgrade the stock, citing a stabilized core business and promising momentum in its innovation pipeline. With new product launches in both livestock and pet health, Elanco is better positioned for growth—though it still faces stiff competition from larger rivals like Zoetis and Merck.
Analyst Brandon Vazquez said meetings and conversations centered on current momentum <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">and pipeline efforts</a>, giving the confidence to upgrade.
The analyst highlights that the core business (ex-innovation, or about 85% of sales) has stabilized due to improved execution or, bluntly, years of share losses that have made less competitive segments less impactful to the P&amp;L statement.
Also Read: <a href="https://www.benzinga.com/25/05/45257358/animal-health-elanco-sees-momentum-building-despite-challenging-market-backdrop-q1-earnings-beat-estimates" target="_blank" rel="noreferrer noopener">Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide</a>
The company&#8217;s growing lineup of recent launches may also help drive sales of older products over time, Vazquez says.
Why It Matters: These products alone could contribute around five percentage points to overall growth in 2025. William Blair upgraded Elanco&#8217;s rating from <a href="https://www.benzinga.com/quote/ELAN/analyst-ratings" target="_blank" rel="noreferrer noopener">Market Perform to Outperform</a>.
Recently, the European Medicines Agency&#8217;s Committee for Veterinary Medicinal Products granted a positive opinion to Elanco&#8217;s Zenrelia (ilunocitinib). The company expects approval and product supply in the market before the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45914288/elanco-receives-positive-opinion-on-zenrelia-ilunocitinib-from-eus-committee-for-veterinary-medici" rel="noreferrer noopener">end of the third quarter</a>.
The management noted that when new customers start using newer farm animal products like Bovaer and Experior—which currently face little to no competition—it can also increase demand for older products like Rumensin.
William notes that Elanco faces tough competition from big, well-funded companies that are also investing heavily in developing new products.
Competition: Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) JAK inhibitor could affect how well Elanco's drug Zenrelia performs globally. Merck's drug is expected to have fewer safety concerns.
Zoetis Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) also has a strong track record of improving existing products, analysts say. That could make it harder for Elanco's new drugs to gain market share.
Price Action: ELAN stock is up 3.05% at $14.18 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46119440/why-did-this-uae-based-fund-just-purchase-100m-worth-of-trump-affiliated-wlfi-tokens" target="_blank" rel="noreferrer noopener">Why Did This UAE-Based Fund Just Purchase $100M Worth Of Trump-Affiliated WLFI Tokens?</a></li>
</ul>
Image: Shutterstock

Analyst Color

Large Cap

News

Upgrades

Health Care

Analyst Ratings

Movers

General

ELAN

Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise

McCormick shares are trading higher after the company reported better-than-expected Q2 EPS and sales.

<a href="https://www.reuters.com/world/us/walmart-close-sams-club-fulfillment-center-texas-affecting-hundreds-employees-2025-06-26/">https://www.reuters.com/world/us/walmart-close-sams-club-fulfillment-center-texas-affecting-hundreds-employees-2025-06-26/</a>

'Walmart to close Sam's Club fulfillment center in Texas, affecting hundreds of employees'- Reuters

HNI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HNI#NYSE">HNI</a>) today celebrated the official ribbon cutting of a new solar installation at HNI's Highway 61 facility in Muscatine, Iowa. This project marks a significant milestone in local sustainability efforts.
The new solar installation, located on HNI's Highway 61 campus, will provide clean, renewable energy to help power operations at the facility. This is HNI's largest solar installation to date and will generate more than 1,500 MWh annually, equivalent to approximately 7% of the facility's annual electricity consumption. The array will significantly reduce greenhouse gas emissions and the transition to a more sustainable energy future.
 &nbsp;

HNI Corp. Announces New Solar Installation At HNI's Highway 61 Facility In Muscatine, Iowa

Crowdfunding syndicator and social media celebrity <a href="https://www.benzinga.com/personal-finance/management/25/06/45842057/grant-cardone-explains-why-we-are-becoming-a-renter-nation-many-people-dont-want-to-commit-to-30-years-theyre-on-the-move">Grant Cardone</a> is known for his robust self-promotion when engaging people to invest in his real estate projects. One lawsuit, initially filed in 2020 but dismissed in 2023, claimed the real estate celeb misled investors. The lawsuit is back on the table after a panel of three California U.S. appeals judges reversed the original decision.
<h2 class="wp-block-heading">‘Overpromising Returns'</h2>
In 2020, Luis Pino sued Cardone and his Aventura-based company, Cardone Capital, as well as two real estate funds, alleging that Cardone had overpromised returns and failed to fully disclose the fees his company collected. Pino's daughter, Christine Pino, was named the new plaintiff in an amended lawsuit upon the death of her father,<a href="https://therealdeal.com/miami/2025/06/17/appeals-court-reverses-dismissal-of-grant-cardone-suit/"> The Real Deal</a> reports.
Don't Miss:
<ul class="wp-block-list">
<li>GoSun's breakthrough rooftop EV charger already has 2,000+ units reserved —<a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor"> become an investor in this $41.3M clean energy brand today</a>.</li>
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market.<a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment"> Back a bold new approach to cancer treatment with high-growth potential.</a></li>
</ul>
Inglewood, California, resident Pino invested $10,000 in two of Cardone's funds, named in the complaint filed in Los Angeles federal court. Pino's attorneys did not respond to requests for comments by The Real Deal. Cardone, however, was more forthcoming, saying that Luis Pino refused Cardone's offer to return his $10,000 and that Pino was "happy with it."
"It is obvious to any savvy person that this is a legal attempt to get a monetary settlement from me, believing I will tap out to make negative publicity go away," Cardone told the outlet. "There has been no financial damage, and the investment is outperforming our objectives. I have spent millions to defend this frivolous lawsuit over a $10,000 investment and will continue to do so. Cardone Capital has one of the best performance records in the industry."
Cardone went on to claim that Cardone Capital had distributed $100 million to its investors over the past 12 months, including $20 million this month, with an average return of nearly 7%.
"During a time when syndicators have failed [and] are returning assets to lenders, and while REITs struggle with distributions and redemptions, Cardone Capital continues to make monthly and quarterly distributions," Cardone said. "We are on track to exceed all expectations previously targeted."
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, with minimum investments as low as $100</a>.
<h2 class="wp-block-heading">A Warning</h2>
The three judges in Christine Pino's claim cite a letter from the Securities and Exchange Commission, which warned Cardone not to include projected investment returns and distributions from his offering memos.&nbsp;
<h2 class="wp-block-heading">A 10 Million Social Media Following From Which To Recruit</h2>
Cardone's social media is a powerful recruiting tool. According to The Real Deal, he has 10 million followers across all his platforms, from which he often attracts small investors. He utilizes his media reach to sell minority stakes in his multifamily properties, which comprise thousands of units, as well as a Bitcoin fund owned by Cardone Capital and his affiliates.&nbsp;
<h2 class="wp-block-heading">An Outspoken Critic Of Jerome Powell</h2>
Recently, Cardone has been an<a href="https://www.benzinga.com/markets/25/06/45868743/grant-cardone-says-jerome-powell-has-done-more-damage-to-american-middle-class-than-any-other-single"> outspoken critic of Fed Chair Jerome Powell</a>, accusing him of contributing to the housing crisis, specifically due to high interest rates, which Cardone claims have deterred people from buying homes despite a decline in inflation.
"He [Jerome Powell] has done more damage to the middle class and to housing in this country than any other single Fed or any decision that has ever been made out of Washington, D.C.," Cardone stated on Fox Business' Morning With Maria.&nbsp;
See Next:
<ul class="wp-block-list">
<li>$100k in assets? Maximize your retirement and cut down on taxes:<a href="https://www.benzinga.com/money/wideradvisor-retirement-planning"> Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>

Personal Finance

Grant Cardone's Previously Dismissed Lawsuit Is Back—And He Swears He'll Clear His Name

The U.S. stock market has just broken into a new uncharted territory, with the S&amp;P 500 index hitting a new record high on Thursday, surpassing its previous all-time high <a href="https://www.benzinga.com/markets">set on February 19.</a>
That's a major comeback considering how things looked just a few months ago.
On April 7, stocks were in a state of panic. Fears over Trump&#8217;s tariffs and a potential recession sparked a steep selloff, with the S&amp;P tumbling 21% from its February highs.
However, since then, the market has rebounded by a stunning 27%, driven by easing trade tensions, stronger-than-expected corporate earnings, and receding recession fears.
Now, investors are turning their attention to what comes next, and if history is any guide, the rally may just be getting started.
<h2 class="wp-block-heading">A Golden Cross Is Coming: Why It Matters</h2>
The S&amp;P 500 – as tracked by the Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) – is close to flashing what traders call a golden cross. 
That's when the 50-day moving average rises above the 200-day moving average—a sign that momentum is picking up and a new leg higher could be underway.
While it may sound like a niche signal, the golden cross has proven to be a historically reliable indicator of bull markets.
Since World War II, the golden cross signal has appeared 37 times on the S&amp;P 500, and nearly three out of four times, it has led to gains.
A simple strategy of buying the index at the golden cross and selling at the following death cross – when the 50-day crosses below the 200-day average – would have shown: 
<ul class="wp-block-list">
<li>Average gain per trade: +14.7%</li>
<li>Winning ratio: 73% (27 out of 37 trades ended in profit)</li>
<li>Average trade duration: 565 days</li>
</ul>
The strongest signal on record occurred in 1994, resulting in a remarkable 120.9% gain over a four-year period.
And looking at more recent history—since 1995—the results still shine.
On average, each trade delivered a 15.5% total return, and 10 out of 13 trades were profitable, for a win rate of 77%.
The strongest performance occurred during the 2012–2015 period, with a 51.4% gain, while the briefest and worst-performing signal resulted in a 4.7% loss over just 21 days in early 2016.
Most recently, the 2023–2025 golden-cross trade posted a solid 30.8% gain.
<h3 class="wp-block-heading">Golden Cross Strategy On The S&amp;P 500</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Date Entry</th>
<th>Date Exit</th>
<th>Length (Days)</th>
<th>S&amp;P 500 Price at Buy</th>
<th>S&amp;P 500 Price at Sell</th>
<th>Performance</th>
<th>Annualized Gain</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998-12-09</td>
<td>1999-11-05</td>
<td>331</td>
<td>1,181.38</td>
<td>1,363.55</td>
<td>+15.42%</td>
<td>+17.28%</td>
</tr>
<tr>
<td>1999-11-12</td>
<td>2000-10-31</td>
<td>355</td>
<td>1,383.04</td>
<td>1,401.18</td>
<td>+1.31%</td>
<td>+1.34%</td>
</tr>
<tr>
<td>2003-05-15</td>
<td>2004-08-19</td>
<td>462</td>
<td>940.47</td>
<td>1,094.99</td>
<td>+16.43%</td>
<td>+12.51%</td>
</tr>
<tr>
<td>2004-11-08</td>
<td>2006-07-20</td>
<td>619</td>
<td>1,166.17</td>
<td>1,260.21</td>
<td>+8.06%</td>
<td>+4.65%</td>
</tr>
<tr>
<td>2006-09-13</td>
<td>2007-12-24</td>
<td>467</td>
<td>1,312.33</td>
<td>1,484.55</td>
<td>+13.12%</td>
<td>+9.70%</td>
</tr>
<tr>
<td>2009-06-24</td>
<td>2010-07-06</td>
<td>377</td>
<td>896.31</td>
<td>1,028.09</td>
<td>+14.70%</td>
<td>+13.89%</td>
</tr>
<tr>
<td>2010-10-25</td>
<td>2011-08-15</td>
<td>294</td>
<td>1,184.74</td>
<td>1,178.86</td>
<td>-0.50%</td>
<td>-0.62%</td>
</tr>
<tr>
<td>2012-02-01</td>
<td>2015-08-31</td>
<td>1,308</td>
<td>1,312.45</td>
<td>1,986.73</td>
<td>+51.38%</td>
<td>+13.26%</td>
</tr>
<tr>
<td>2015-12-22</td>
<td>2016-01-12</td>
<td>21</td>
<td>2,023.15</td>
<td>1,927.83</td>
<td>-4.71%</td>
<td>-53.92%</td>
</tr>
<tr>
<td>2016-04-26</td>
<td>2018-12-10</td>
<td>958</td>
<td>2,089.84</td>
<td>2,630.86</td>
<td>+25.89%</td>
<td>+9.39%</td>
</tr>
<tr>
<td>2019-04-02</td>
<td>2020-03-31</td>
<td>364</td>
<td>2,868.24</td>
<td>2,614.69</td>
<td>-8.84%</td>
<td>-8.84%</td>
</tr>
<tr>
<td>2020-07-10</td>
<td>2022-03-15</td>
<td>613</td>
<td>3,152.47</td>
<td>4,188.82</td>
<td>+32.87%</td>
<td>+17.38%</td>
</tr>
<tr>
<td>2023-02-03</td>
<td>2025-04-15</td>
<td>802</td>
<td>4,136.69</td>
<td>5,411.99</td>
<td>+30.83%</td>
<td>+13.13%</td>
</tr>
</tbody>
<tfoot>
<tr>
<td></td>
<td>Average</td>
<td>578</td>
<td></td>
<td></td>
<td>+15.5%</td>
<td>+6.9%</td>
</tr>
</tfoot>
</table>
<figcaption class="wp-element-caption">Data: TradingView</figcaption></figure>
<h2 class="wp-block-heading">Will Seasonality Boost US Stocks In July?</h2>
Beyond technicals, calendar gains may also help. Seasonal trends show that late June through the end of July has historically been a strong period for the S&amp;P 500.
Analyzing the S&amp;P 500's performance between June 26 and July 31 – or the nearest trading days – over the past 15 years, Seasonax data reveals an average return of +3.46% during this period, with 14 out of 15 years finishing in the green.
The strongest July stretch came in 2016, when the index gained 8.51%. The only loss occurred in 2014, with a modest decline of 1.36%.
In fact, if you had bought the index around June 26 and held it through July 31 for the last 15 years, you would have made money 14 times out of 15.
The average return during that window? 3.46%.
In 2016 and 2020, the index jumped more than 8%. The only time it dropped was in 2014, and even then, the decline was only 1.36%. Most years didn't see big pullbacks either, meaning the risk has been relatively low during this midsummer stretch.
<h3 class="wp-block-heading">S&amp;P 500 Enters Strong Seasonal Window: More Gains To Come?</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Start Date</th>
<th>End Date</th>
<th>S&amp;P 500 Start Price</th>
<th>S&amp;P 500 End Price</th>
<th>Profit (Pts)</th>
<th>% Gain</th>
<th>Max Rise</th>
<th>Max Drawdown</th>
</tr>
</thead>
<tbody>
<tr>
<td>28 Jun 2010</td>
<td>02 Aug 2010</td>
<td>1,074.57</td>
<td>1,125.86</td>
<td>+51.29</td>
<td>+4.77%</td>
<td>+4.77%</td>
<td>-4.84%</td>
</tr>
<tr>
<td>27 Jun 2011</td>
<td>01 Aug 2011</td>
<td>1,280.10</td>
<td>1,286.94</td>
<td>+6.84</td>
<td>+0.53%</td>
<td>+5.71%</td>
<td>0.00%</td>
</tr>
<tr>
<td>26 Jun 2012</td>
<td>31 Jul 2012</td>
<td>1,319.99</td>
<td>1,379.32</td>
<td>+59.33</td>
<td>+4.49%</td>
<td>+5.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>26 Jun 2013</td>
<td>31 Jul 2013</td>
<td>1,603.26</td>
<td>1,685.73</td>
<td>+82.47</td>
<td>+5.14%</td>
<td>+5.76%</td>
<td>0.00%</td>
</tr>
<tr>
<td>26 Jun 2014</td>
<td>31 Jul 2014</td>
<td>1,957.22</td>
<td>1,930.67</td>
<td>-26.55</td>
<td>-1.36%</td>
<td>+1.57%</td>
<td>-1.36%</td>
</tr>
<tr>
<td>26 Jun 2015</td>
<td>31 Jul 2015</td>
<td>2,101.49</td>
<td>2,103.84</td>
<td>+2.35</td>
<td>+0.11%</td>
<td>+1.27%</td>
<td>-2.61%</td>
</tr>
<tr>
<td>27 Jun 2016</td>
<td>01 Aug 2016</td>
<td>2,000.54</td>
<td>2,170.84</td>
<td>+170.30</td>
<td>+8.51%</td>
<td>+8.72%</td>
<td>0.00%</td>
</tr>
<tr>
<td>26 Jun 2017</td>
<td>31 Jul 2017</td>
<td>2,439.07</td>
<td>2,470.30</td>
<td>+31.23</td>
<td>+1.28%</td>
<td>+1.59%</td>
<td>-1.20%</td>
</tr>
<tr>
<td>26 Jun 2018</td>
<td>31 Jul 2018</td>
<td>2,723.06</td>
<td>2,816.29</td>
<td>+93.23</td>
<td>+3.42%</td>
<td>+4.52%</td>
<td>-0.86%</td>
</tr>
<tr>
<td>26 Jun 2019</td>
<td>31 Jul 2019</td>
<td>2,913.78</td>
<td>2,980.38</td>
<td>+66.60</td>
<td>+2.29%</td>
<td>+3.85%</td>
<td>0.00%</td>
</tr>
<tr>
<td>26 Jun 2020</td>
<td>31 Jul 2020</td>
<td>3,009.05</td>
<td>3,271.12</td>
<td>+262.07</td>
<td>+8.71%</td>
<td>+8.87%</td>
<td>0.00%</td>
</tr>
<tr>
<td>28 Jun 2021</td>
<td>02 Aug 2021</td>
<td>4,290.61</td>
<td>4,387.16</td>
<td>+96.55</td>
<td>+2.25%</td>
<td>+3.07%</td>
<td>-0.75%</td>
</tr>
<tr>
<td>27 Jun 2022</td>
<td>01 Aug 2022</td>
<td>3,900.11</td>
<td>4,118.63</td>
<td>+218.52</td>
<td>+5.60%</td>
<td>+5.90%</td>
<td>-2.94%</td>
</tr>
<tr>
<td>26 Jun 2023</td>
<td>31 Jul 2023</td>
<td>4,328.82</td>
<td>4,588.96</td>
<td>+260.14</td>
<td>+6.01%</td>
<td>+6.01%</td>
<td>0.00%</td>
</tr>
<tr>
<td>26 Jun 2024</td>
<td>31 Jul 2024</td>
<td>5,477.90</td>
<td>5,522.30</td>
<td>+44.40</td>
<td>+0.81%</td>
<td>+3.46%</td>
<td>-1.44%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data: Seasonax</figcaption></figure>
<h3 class="wp-block-heading">So, What's the Bottom Line?</h3>
The S&amp;P 500 is breaking records again. A golden cross is forming. And seasonality is in the market's favor. 
Nothing in markets is guaranteed—but history suggests the path ahead could be smoother, and maybe even profitable, for those who stay in.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46096528/nasdaq-100-record-highs-rally-historical-performance">Nasdaq 100 Hits Record Highs After 30% Rally: History Suggests It&#8217;s Not Done Yet</a></li>
</ul>
Photo: Shutterstock

Econ #s

S&P 500 Hits Record Highs—And History Says The Best Is Yet To Come

Nike Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) shares are trading higher Thursday as investors prepare for the company's fourth-quarter earnings report <a href="https://www.benzinga.com/trading-ideas/previews/25/06/46104171/nike-q4-earnings-preview-market-expert-says-things-arent-looking-good">due after market close.</a>
What To Know: Analysts expect Nike to report fourth-quarter revenue of $10.71 billion, down from $12.61 billion in the same quarter last year. Earnings per share are projected to come in at 12 or 13 cents, a drop from 99 cents a year ago.
Although Nike has a strong track record of beating earnings expectations, doing so in nine of the last ten quarters, the stock has declined after eight of the last nine earnings releases. According to Freedom Capital Markets strategist Jay Woods, the market remains skeptical of a near-term turnaround. He noted the stock is still down over 65% from its 2021 highs and warned that any real recovery could take several quarters of consistent growth.
Needham analyst Tom Nikic expressed similar concerns, maintaining a Buy rating but cutting his price target from $75 to $66. He cited ongoing issues with brand momentum and market execution. Other analysts, including those from Truist, Evercore, Deutsche Bank and Barclays, also lowered their price targets ahead of earnings.
Some investors may be eyeing Nike's dividend yield as a reason to hold through the volatility. The company currently offers a 2.63% annual yield or $1.60 per share annually. However, analysts say that potential upside in the near term will depend on Nike's ability to address weak demand in China, improve its North American performance and provide clear updates on growth initiatives like its upcoming product collaboration with SKIMS and its renewed partnership with Amazon.
NKE Price Action: Nike shares were up 2.29% at $62.23 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/46115346/trump-powell-fed-chairman-odds-dollar">Trump&#8217;s Fed Chairman Shortlist Is In: What Investors Need To Know</a></li>
</ul>
Image Via Shutterstock.

What's Going On With Nike Shares Today?

Nike shares are trading higher ahead of the company's Q4 earnings report.

Nano Labs Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) saw a surge in its stock price on Thursday after revealing plans for a new capital raise through a mix of share issuance and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46115312/nano-labs-announces-pricing-of-50-0-million-registered-direct-offering-and-concurrent-private-plac" rel="noreferrer noopener">private warrant placements</a>.
The China-based technology firm entered into a securities purchase agreement with select institutional investors to issue approximately 5.95 million Class A ordinary shares via a registered direct offering.
Alongside this, it will issue an equal number of warrants through a concurrent private placement.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43267473/why-nano-labs-shares-are-seeing-blue-skies-premarket-on-monday" rel="noreferrer noopener">Nano Labs Invests In Weiheng Technology To Power AI Innovation</a>
The combined offer price per share and warrant is set at $8.40, with warrants priced for initial exercise at $10.00 per share. These warrants will be valid for five years following the effective date of registration.
Gross proceeds from the combined transactions are estimated at $50 million, prior to accounting for placement agent fees and related expenses.
The company disclosed it intends to use the raised capital, and any proceeds from future warrant exercises, to acquire Binance Coin (BNB) as part of its digital asset investment strategy.
The offering is expected to close around June 27, 2025, subject to standard closing conditions.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, NA stock has gained over 178% in the past year.
Price Action: NA shares are trading higher by 8.37% to $12.30 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46117348/meta-secures-more-clean-energy-for-power-hungry-ai-and-data-center-growth" target="_blank" rel="noreferrer noopener">Meta Secures More Clean Energy For Power Hungry AI And Data Center Growth</a></li>
</ul>
Image via Shutterstock

Equities

Markets

Tech

What's Going On With Nano Labs Stock On Thursday?

BMO Capital analyst Andrew Strelzik initiates coverage on JBS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBS#NYSE">JBS</a>) with a Outperform rating and announces Price Target of $20.

Price Target

Initiation

BMO Capital Initiates Coverage On JBS with Outperform Rating, Announces Price Target of $20

<a href="https://www.wsj.com/world/europe/eu-considers-lowering-tariffs-on-u-s-imports-in-bid-to-woo-trump-fe070042">https://www.wsj.com/world/europe/eu-considers-lowering-tariffs-on-u-s-imports-in-bid-to-woo-trump-fe070042</a>

'EU Considers Lowering Tariffs on U.S. Imports in Bid to Woo Trump'- WSJ

Macro Economic Events

Market Summary

Economics

Benzinga Market Summary: S&P Nears Record, Micron Beats Earnings Estimates But Stock Pulls Back, US Dollar Index Declines

Management

MTEX

Mannatech Promotes Peter Griscom To COO, Effective July 1, 2025

Roth Capital analyst Sean McGowan maintains Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) with a Buy and raises the price target from $46 to $52.

CELH

Roth Capital Maintains Buy on Celsius Holdings, Raises Price Target to $52

Roth Capital analyst Scott Stember maintains Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) with a Neutral and lowers the price target from $37 to $30.

Roth Capital Maintains Neutral on Winnebago Industries, Lowers Price Target to $30

<a href="https://www.bloomberg.com/news/articles/2025-06-26/fed-s-collins-says-july-likely-too-early-for-interest-rate-cut?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-26/fed-s-collins-says-july-likely-too-early-for-interest-rate-cut?embedded-checkout=true</a>

'Fed's Collins Says July Is Likely Too Early for Interest-Rate Cut'- Bloomberg

Bank of America Securities (BofA) reiterated a Buy rating on Citigroup, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), raising the <a target="_blank" href="https://www.benzinga.com/quote/C/analyst-ratings" rel="noreferrer noopener">price forecast from $89 to $100</a>.
According to BofA Securities, Citi&#8217;s overhaul remains one of the toughest in the corporate world. Still, recent moves like global consumer exits, de-risking, tech upgrades, and new hires suggest CEO Jane Fraser&#8217;s 2022 vision may finally have a real shot at success.
All five of Citi&#8217;s business segments have shown improved profitability over the past year.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/06/45858626/citigroup-rolls-out-summer-remote-work-option-for-employees-while-rivals-argue-you-cant-learn-working-from-your-basement" rel="noreferrer noopener">Citigroup Rolls Out Summer Remote Work Option For Employees, While Rivals Argue&#8217; You Can&#8217;t Learn Working From Your Basement&#8217;</a>
Wealth and banking, now under refreshed leadership, have become more focused. Management aims for a 15%–20% Return on Tangible Common Equity (ROTCE) in wealth by 2026, up from an estimated ~10% in FY25.
With a low base, there&#8217;s ample room for gains, and Citi is expected to sustainably cross the 10% consolidated ROTCE mark from 2026, BofA Securities writes.
Share repurchases are expected to pick up pace in the second half of 2025, with BofA Securities and consensus forecasting $2.4 billion and $2.1 billion per quarter, respectively.
A more stable regulatory environment should give management greater flexibility on costs after several years of constraint.
Additionally, BofA Securities&#8217; economic outlook points to stronger GDP growth, which could ease credit costs in 2026, supported by reserve assumptions based on a 5.1% weighted average unemployment rate.
BofA Securities notes that the 2026 consensus forecast assumes Citigroup will only meet the low end of its strategic goals, suggesting potential for upward revisions.
BofA Securities raised its FY26 EPS estimate from $9.85 to $10 and increased the price target from $89 to $100, implying 10x 2026 P/E and 0.95x forward P/TBV. It also raised valuation multiples on improved visibility into ROTCE.
Price Action: C shares are trading higher by 2.4% to $84.63 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46117348/meta-secures-more-clean-energy-for-power-hungry-ai-and-data-center-growth" target="_blank" rel="noreferrer noopener">Meta Secures More Clean Energy For Power Hungry AI And Data Center Growth</a></li>
</ul>
Photo via Shutterstock

Reiteration

Citigroup's Massive Overhaul Under Jane Fraser Shows Signs Of Paying Off

Evercore ISI Group analyst Robert Ottenstein maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Outperform and raises the price target from $90 to $100.

Comments

Critical Infr Techs

뉴스

에 대한 최신 뉴스 Critical Infr Techs (OTC:CITLF) 주식

뉴스

파트너 / 기고자

벤징가 글로벌